Who are ENO Lime's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tums, Milk of Magnesia, Magnesium aluminum hydroxide, Maalox plus Benadryl, Oral Maalox/ Mylanta, Sodium Bicarbonate and Sodium chloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eno-lime.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ENO Lime — Competitive Intelligence Brief

ENO Lime (ENO Lime) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antacid. Area: Gastroenterology.

phase 3 Antacid Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

ENO Lime (ENO Lime) — HALEON. ENO Lime is an antacid that neutralizes stomach acid to relieve heartburn and indigestion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ENO Lime TARGET	ENO Lime	HALEON	phase 3	Antacid
Tums	calcium carbonate	Generic (multiple manufacturers)	marketed	Antacid, Calcium supplement	Gastric acid (direct neutralization)	1930-01-01
Milk of Magnesia	magnesium hydroxide	Generic (multiple manufacturers)	marketed	Osmotic laxative, Antacid	Gastric acid (direct neutralization) + osmotic effect in intestine	1880-01-01
Magnesium aluminum hydroxide	Magnesium aluminum hydroxide	Isfahan University of Medical Sciences	marketed	Antacid
Maalox plus Benadryl	Maalox plus Benadryl	The University of Texas Health Science Center, Houston	marketed	Antacid with antihistamine	H1 receptor (diphenhydramine component); direct acid neutralization (antacid component)
Oral Maalox/ Mylanta	Oral Maalox/ Mylanta	Stony Brook University	marketed	Antacid combination
Sodium Bicarbonate and Sodium chloride	Sodium Bicarbonate and Sodium chloride	University Hospital, Clermont-Ferrand	marketed	Electrolyte and antacid combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antacid class)

Amorphical Ltd. · 1 drug in this class
Bosnalijek D.D · 1 drug in this class
HALEON · 1 drug in this class
Isfahan University of Medical Sciences · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
POZEN · 1 drug in this class
Western Galilee Hospital-Nahariya · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ENO Lime — Competitive Intelligence Brief. https://druglandscape.com/ci/eno-lime. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab